Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient AMERICAN JOURNAL OF TRANSPLANTATION Lipshutz, G. S., Mihara, N., Wong, R., Wallace, W. D., Allen-Auerbach, M., Dorigo, O., Rao, P. N., Pham, P. T., Pham, P. T. 2009; 9 (2): 428-432

Abstract

Posttransplant malignancy developing in an allograft is an uncommon complication of organ transplantation. The tumor may represent malignant transformation of donor or recipient cells that were previously normal, metastatic malignancy of recipient origin or malignancy transmitted from organ donor to recipient. Establishing the origin of the malignancy is critical to treatment algorithms. It is generally believed allograft removal and immunosuppression withdrawal will lead to resolution of transmitted malignancies in cases where the renal allograft is the origin. We report a male patient who developed metastatic ovarian malignancy secondary to donor transmission.

View details for DOI 10.1111/j.1600-6143.2008.02507.x

View details for Web of Science ID 000262781400027

View details for PubMedID 19178417